G1SecL05: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
|||
| Line 8: | Line 8: | ||
==Introduction to LYMErix == | ==Introduction to LYMErix == | ||
LYMErix, implemented in 1998 by the FDA,is a noninfectious vaccine that uses recombinant ospA expressed by ''Escherichia coli'' absorbed into an aluminum hydroxide adjuvant to stimulate immune response during injection. The formation of specific IgG anti- ospA antibodies including those directed towards the epitope LA-2that resulted following vaccination aimed at traveling to the tick’s mid-gut in order to interact with ''B.burgdorferi'', preventing transmission of Lyme disease to host. | LYMErix, implemented in 1998 by the FDA,is a noninfectious vaccine that uses recombinant ospA expressed by ''Escherichia coli'' absorbed into an aluminum hydroxide adjuvant to stimulate immune response during injection. The formation of specific IgG anti- ospA antibodies including those directed towards the epitope LA-2that resulted following vaccination aimed at traveling to the tick’s mid-gut in order to interact with ''B.burgdorferi'', preventing transmission of Lyme disease to host<ref name= "quantitative">PMID:21217172</ref>. | ||
[[Image:LYMErix.jpg|left|thumb|Retail Packaging of LYMErix™]] | [[Image:LYMErix.jpg|left|thumb|Retail Packaging of LYMErix™]] | ||
